Des Moines, Iowa (PRWEB) May 06, 2013
Results from AREDS2 presented yesterday at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting and published online in the Journal of the American Medical Association report an 18 percent reduction in progression to advanced AMD in subjects who received 10 mg FloraGLO Lutein and 2 mg OPTISHARP Zeaxanthin in addition to an AREDS supplement without beta carotene when compared to the original AREDS supplement with beta carotene.
Most importantly, NEI also recommends improving the safety and efficacy of the AREDS supplement by removing beta carotene and replacing it with 10 mg FloraGLO® Lutein and 2 mg OPTISHARP® Zeaxanthin.
Additionally, a significant reduction of 26 percent in progression to advanced AMD was found in a subgroup analysis in subjects with the lowest quintile of dietary intake of lutein and zeaxanthin (median 0.7 mg per day) but supplemented with 10 mg FloraGLO Lutein and 2 mg OPTISHARP® Zeaxanthin. The AREDS2 study participants were well nourished with a diet high in carotenoids and vegetables. The authors suggest that a greater reduction in AMD progression may have been demonstrated if the subjects’ diets had been more representative to those of the general U.S. population. In the U.S., the dietary intake of lutein and zeaxanthin is typically less than 1 mg per day. This amount is well below the 10 mg lutein and 2 mg zeaxanthin that the study has proven to be effective.
“We are gratified the NEI is recommending that lutein and zeaxanthin be added to AREDS formulations as the new standard of care,” said Jeff Flora, president, human nutrition and health division of Kemin. “This is a meaningful step in further reducing the progression to advanced AMD as the population at risk continues to grow.”
AREDS2 is a randomized trial conducted in more than 80 sites across the U.S. by the National Eye Institute (NEI) of the National Institutes of Health (NIH). This study follows AREDS1, which was published in 2001 and found that people at high risk of developing advanced stages of AMD lowered their risk by about 25 percent when treated with a high-dose combination of vitamin C, vitamin E, beta-carotene, and zinc. AREDS2 assessed the effects of oral supplementation of certain eye nutrients in more than 4,000 participants ranging from 50-85 years of age, most of whom at the time of enrollment had intermediate AMD. It is the largest trial to date testing the effectiveness of lutein, zeaxanthin and omega-3 in adults with AMD. The AREDS2 study also found that circulating blood levels of lutein and zeaxanthin increased significantly in those receiving supplements, which may have a protective effect in eye disease.
About FloraGLO® and OPTISHARP®
FloraGLO® Lutein is manufactured by Kemin, and OPTISHARP® Zeaxanthin is manufactured and formulated by DSM. FloraGLO Lutein and OPTISHARP Zeaxanthin are trusted sources of lutein and zeaxanthin because of their quality and established safety profile. Actilease® technology maximizes nutrient absorption to achieve optimum bioavailability.
Kemin – Inspired Molecular Solutions™
Kemin (http://www.kemin.com) provides “inspired molecular solutions” specifically developed to provide nutrition and health benefits for humans and animals. Committed to feed and food safety, Kemin maintains top-of-the-line manufacturing facilities where approximately 500 specialty ingredients are made for the global feed and food industries as well as the health, nutrition and beauty markets. A privately held, family-owned and operated company, Kemin has more than 1,600 employees and operates in 90 countries with manufacturing facilities in Belgium, Brazil, China, India, Italy, Singapore, South Africa and the United States.
FloraGLO® is a registered trademark of Kemin Industries, Inc.
OPTISHARP® is a registered trademark of DSM
Actilease® is a registered trademark of DSM
1Kemin Foods, L.C. internal memorandum based on PubMed search